Switch to:
More From Other Websites
Alkermes CEO, Richard Pops, On ALKS 5461 And Challenges In Developing New Drugs For Depression Feb 09 2016
Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Conferences Feb 02 2016
Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Conferences Feb 02 2016
Alkermes short bets built up ahead of depression drug setback Jan 28 2016
Alkermes Initiates Early-Stage Study on Alzheimer's Drug Jan 27 2016
Alkermes Announces Initiation of Phase 1 Clinical Study of New CNS Drug Candidate ALKS 7119 Jan 25 2016
Alkermes Announces Initiation of Phase 1 Clinical Study of New CNS Drug Candidate ALKS 7119 Jan 25 2016
Alkermes Announces Initiation of Phase 1 Clinical Study of New CNS Drug Candidate ALKS 7119 Jan 25 2016
8 Things That Could Lift Biotech Stocks Out of Bear Market Jan 24 2016
4 Stocks That Punished Shareholders Last Week Jan 23 2016
Alkermes Hit 52-Week Low on Unfavorable Phase III Data Jan 22 2016
Alkermes Learns Makeovers Aren't Easy Jan 22 2016
[$$] Business Watch Jan 21 2016
Why These 5 Stocks Are Plummeting Today Jan 21 2016
[$$] Alkermes Depression Drug Disappoints Jan 21 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of... Jan 21 2016
Alkermes Hits Two-Year Low On Depression Drug Failure Jan 21 2016
Alkermes downgraded by Morgan Stanley and JP Morgan Jan 21 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GuruFocus Premium Plus Membership

FEEDBACK